Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells
With greater accessibility and an increased number of patients being treated with CAR T cell therapy, real-world toxicity continues to remain a significant challenge to its widespread adoption. We have previously shown that allogeneic umbilical cord blood-derived (UCB) regulatory T cells (Tregs) can...
Main Authors: | Ke Zeng, Meixian Huang, Mi-Ae Lyu, Joseph D. Khoury, Sairah Ahmed, Krina K. Patel, Boro Dropulić, Jane Reese-Koc, Paolo F. Caimi, Tara Sadeghi, Marcos de Lima, Christopher R. Flowers, Simrit Parmar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/14/1880 |
Similar Items
-
Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus
by: Mi-Ae Lyu, et al.
Published: (2023-09-01) -
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells
by: Blandine Caël, et al.
Published: (2022-06-01) -
A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023
by: Huimin Li, et al.
Published: (2023-12-01) -
CAR T-cells for T-cell acute lymphoblastic leukemia
by: Marie Emilie Dourthe, et al.
Published: (2024-06-01) -
Case report: CAR-T cell therapy-induced cardiac tamponade
by: Sacha Sarfati, et al.
Published: (2023-03-01)